Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Apr
27
Today In Oncology
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside